- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Clarivate Releases Annual Drugs To Watch Report
The report highlights various treatments for HIV, Parkinson's disease, Crohn's disease, alopecia, multiple myeloma, and breast cancer.
Clarivate Plc announced the release of its annual Drugs to Watch report. In its 10th year, the Drugs to Watch report provides in-depth predictive analysis of drugs with the potential to transform treatment paradigms and serve unmet patient needs. The report serves as an industry resource in an ever-evolving drug innovation landscape–with more than 70 drugs having been identified as Drugs to Watch.
This analysis identifies drugs entering the market or launching key indications in 2023 which are predicted to achieve blockbuster status by 2027 or be clinical game changers for millions of patients worldwide. Clarivate analysts identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1 billion within five years. These promising advancements include a broad spectrum of therapeutic developments for rare diseases and tough-to-treat conditions, including HIV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer.
Continue reading this story here.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
